Dr Su Metcalfe
Dr Su Metcalfe is pleased to consider applications from prospective PhD students.
1: Application of nanotherapy to target endogenous neural stem cells in vivo for treatment of neurodegenerative diseases. 2: Application of targeted nanotherapy to control antigen-specific immune responses. 3: Exploitation of leukaemia inhibitory factor (LIF) as a therapy via the LIF-nano device. 4: Exploiting Nanog via MARCH-7, an E-3 ligase that controls the LIF receptor.
Symplectic Elements feed provided by Research Information, University of Cambridge
Dong H, Fahmy TM, Metcalfe SM, Morton SL, Dong X, Inverardi L, Adams DB, Gao W, Wang H. (2012), ?Immuno-isolation of pancreatic islet allografts using pegylated nanotherapy leads to long-term normoglycemia in full MHC mismatch recipient mice.? PLoS One. 2012;7(12) 7 (12) Metcalfe SM (2011), ?LIF in the regulation of T-cell fate and as a potential therapeutic.? Genes Immun 12(3):157-68 Details Metcalfe SM, Fahmy TM (2011), ?Targeted nanotherapy for induction of therapeutic immune responses.? Trends Mol Med Details Metcalfe SM (2011), ?Multiple sclerosis: One protein, two healing properties.? Nature 477(7364):287-8 Details LH Thompson, RA Whiston, Y Rakhimov, C Taccioli, C Liu, , C Croce, and SM Metcalfe (2010) A LIF/Nanog axis is revealed in T lymphocytes that lack MARCH-7, a RINGv E3 ligase that regulates the LIF-receptor. Cell Cycle 9:20; 4213-422; October 15, 2010 J Park, W Gao, R Whiston, T B. Strom, S Metcalfe, and T M. Fahmy (2010) Modulation of CD4+ T Lymphocyte Lineage Outcomes with Targeted, Nanoparticle-Mediated Cytokine Delivery. Mol Pharm 8(1):143-52; WGao, LThompson, QZhou, PPutheti, TMFahmy, TBStrom, and Su M. Metcalfe (2009) Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6. Cell Cycle 8:9, 1444-1450, 2009.